Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03953820 · ClinicalTrials.gov registry record · Phase 1

Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study

A Phase 1 study of Epilepsy, sponsored by Aquestive Therapeutics.

Completed
Registry status
Phase 1
Development phase
31
Enrollment target
3
Study locations

NCT03953820: Completed Phase 1 study of Epilepsy, sponsored by Aquestive Therapeutics.

NCT03953820 is a Phase 1 study of Epilepsy that has completed, run by Aquestive Therapeutics. The registered enrollment target is 31 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03953820, a Phase 1 study of Epilepsy, has completed, sponsored by Aquestive Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
31 participants
Enrollment target
3
Study locations

Study Summary

This was a multiple centers, single-dose, open-label, randomized two-sequence crossover, two-period study to evaluate the pharmacokinetics (PK) of single doses of Diazepam Buccal Film (DBF) compared with Diastat® Rectal Gel (DRG) under fed conditions in adult male and female participants on a stable concomitant regimen of anti-epileptic drugs for the treatment of epilepsy.

Primary Outcome

Area Under Plasma Concentration-Time Curve From Time Zero to the last non-zero concentration

Conditions Studied

Interventions

  • DRUG Diazepam Buccal Film
  • DRUG Diastat® Rectal Gel (Valeant Pharmaceuticals USA)

Study Locations (3)

Florida

  • Clinical Trials of Florida, LLC - Miami
  • Bioclinica Research - Orlando
  • Florida Premier Research Institute, LLC - Winter Park

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2019-04-13
Est. Completion 2019-07-31
Phase Phase 1
Aquestive Therapeutics

6 total trials

What the finished NCT03953820 record still lists

NCT03953820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Diazepam Buccal Film is the first listed.

NCT03953820 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03953820 about?

NCT03953820 is a clinical study titled "Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study". This was a multiple centers, single-dose, open-label, randomized two-sequence crossover, two-period study to evaluate the pharmacokinetics (PK) of single doses of Diazepam Buccal Film (DBF) compared with Diastat® Rectal Gel (DRG) under fed conditions in adult male and female participants on a stable...

What is the current status of trial NCT03953820?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2019-04-13. Estimated completion is 2019-07-31.

What conditions does trial NCT03953820 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT03953820?

The interventions under investigation include: Diazepam Buccal Film (DRUG), Diastat® Rectal Gel (Valeant Pharmaceuticals USA) (DRUG).

Who is sponsoring clinical trial NCT03953820?

This trial is sponsored by Aquestive Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03953820 being conducted?

This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03953820's enrollment target sits among peer trials

31 107th of 160 higher than 53 of 160 other Epilepsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03953820, the US trial registry maintained by the National Library of Medicine. NCT03953820 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.